The CODIAC Extension study, sponsored by Charles University, aims to evaluate the effectiveness of transitioning patients with Type 1 Diabetes from an open-source automated insulin delivery system (AndroidAPS) to commercially available systems (Control-IQ and MiniMed 780G). This study is significant as it addresses the growing market for automated insulin delivery systems, which are increasingly being adopted for better glycemic control. The findings may influence market dynamics by providing comparative data that could affect clinician and patient preferences, potentially impacting sales and market share of the involved commercial systems. Additionally, the study's outcomes may inform future product development and regulatory strategies for AID systems.